New targets for antibiotics

University of Illinois at Chicago researchers have identified new sites on the bacterial cell's protein-making machinery where antibiotics can be delivered to treat infections.

"The primary challenge of antibiotic therapy has been fighting infections caused by the pathogens which became resistant to antibiotics," says Alexander Mankin, professor and associate director of UIC's Center for Pharmaceutical Biotechnology and lead investigator of the study. "Not a single class of drugs has escaped the inevitable emergence of resistance."

At present, Mankin said, "the constant development of new drugs is the only available strategy to keep up with the ever-growing variety of antibiotic-resistant pathogens."

Mankin and his research team are looking for new vulnerable sites on bacteria where drugs can be delivered to fight the infections.

"First we need to find the target, and then the weapons can be developed," he said.

In the study, which is published in the Journal of Biological Chemistry, UIC researchers divided a ribosome -- the main apparatus within the cell that makes protein, and one of the best antibiotic targets -- into specific sections. Random genetic mutations were engineered in each area, and the researchers looked for those alterations that stopped the ribosome from making proteins.

Of the thousands of mutations tested, 77 were detrimental to the function of the ribosome. The regions where those mutations lie can be targeted by new antibiotics, which may be used to treat such diseases as tuberculosis and pneumonia, Mankin said.

"If we find drugs that can bind to these regions, they will likely kill the pathogenic cell," he said.

According to Mankin, the development of microbial genomics brought new hope for the development of antibiotics, but few successful drug candidates have been produced using this method.

An alternative approach is to "follow the lead of nature, and develop new drugs that act on the targets in the course of evolution."

"The ribosome is the perfect target," he said. "More than half of all known antibiotics arrest cell growth by interfering with the ribosomal functions and inhibiting protein synthesis. This is an innovative concept, targeting new sites in the ribosome."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New CAR T-cell therapy shows promise against aggressive HER2+ breast cancer